Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers
- PMID: 3519635
Bioaffinity therapy with antibodies and drugs bound to soluble synthetic polymers
Abstract
Soluble synthetic copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA) containing different oligopeptide side-sequences were tested as transport molecules for drugs and anti-Thy 1.2 antibodies in affinity therapy. As target cells, T lymphocytes were studied. (1) HPMA copolymers containing targeting anti-Thy 1.2 antibodies are 70 times more cytotoxic against T lymphocytes than HPMA copolymers with non-specific immunoglobulin. (2) Daunomycin conjugated to a biodegradable side-sequence (Gly-Phe-Leu-Gly) is effective in a concentration 100 times lower than daunomycin conjugated to a non-cleavable sequence (Gly-Gly). (3) HPMA copolymers containing drug and targeting antibodies are effective both in vitro and in vivo.
Similar articles
-
Antibody-targeted polymer-bound drugs.Folia Microbiol (Praha). 1995;40(4):367-84. doi: 10.1007/BF02814745. Folia Microbiol (Praha). 1995. PMID: 8763151 Review.
-
Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody.Clin Immunol Immunopathol. 1988 Jan;46(1):100-14. doi: 10.1016/0090-1229(88)90010-4. Clin Immunol Immunopathol. 1988. PMID: 2891460
-
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro.Br J Cancer. 1987 Feb;55(2):165-74. doi: 10.1038/bjc.1987.33. Br J Cancer. 1987. PMID: 3468994 Free PMC article.
-
Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.J Control Release. 2000 Feb 14;64(1-3):241-61. doi: 10.1016/s0168-3659(99)00140-6. J Control Release. 2000. PMID: 10640661
-
Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers.Curr Pharm Biotechnol. 2003 Oct;4(5):311-22. doi: 10.2174/1389201033489711. Curr Pharm Biotechnol. 2003. PMID: 14529421 Review.
Cited by
-
Antibody-targeted polymer-bound drugs.Folia Microbiol (Praha). 1995;40(4):367-84. doi: 10.1007/BF02814745. Folia Microbiol (Praha). 1995. PMID: 8763151 Review.
-
Hydrophilic biomaterials: From crosslinked and self-assembled hydrogels to polymer-drug conjugates and drug-free macromolecular therapeutics.J Control Release. 2024 Sep;373:1-22. doi: 10.1016/j.jconrel.2024.05.012. Epub 2024 May 17. J Control Release. 2024. PMID: 38734315
-
Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.Br J Cancer. 1988 Feb;57(2):147-56. doi: 10.1038/bjc.1988.31. Br J Cancer. 1988. PMID: 3358905 Free PMC article.
-
HPMA copolymers: origins, early developments, present, and future.Adv Drug Deliv Rev. 2010 Feb 17;62(2):122-49. doi: 10.1016/j.addr.2009.10.004. Epub 2009 Nov 14. Adv Drug Deliv Rev. 2010. PMID: 19919846 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials